Top Markets
Coin of the day
Lysogene S.A. Lysogene S.A.

Lysogene S.A.

LYS
Rank in Stocks #36618
Lysogene S.A. is a biopharmaceutical firm specializing in gene therapy,... Lysogene S.A. is a biopharmaceutical firm specializing in gene therapy, dedicated to discovering and advancing treatments for children affected by severe neurodegenerative lysosomal storage disorders. Its development pipeline includes LYS-SAF302, which is currently undergoing Phase II/III clinical trials for mucopolysaccharidosis type IIIA (MPS IIIA). Another promising candidate, LYS-GM101, is in Phase I/II development, targeting GM1 gangliosidosis. The company has also forged a research alliance with the Weizmann Institute of Science to pioneer novel adeno-associated virus (AAV) gene therapy approaches for conditions such as neuronopathic Gaucher disease, Parkinson's disease, and other related illnesses. Lysogene S.A. was established in 2009 and is headquartered in Neuilly-sur-Seine, France.
Share Price
$0.30221445
Last synced: 2023-05-22
Market Cap
$2.49M
Change (1 day)
-0.10%
Change (1 year)
0.00%
Country
FR
Trade Lysogene S.A. (LYS)

Category

P/B ratio for Lysogene S.A. (LYS)
P/B ratio as of 2026 TTM: 0
According to Lysogene S.A. latest financial reports and stock price the company's current price-to-book ratio (TTM) is 0. At the end of 2026 the company had a P/B ratio of 0.
P/B ratio history for Lysogene S.A. from 2026 to 2026
P/B ratio at the end of each year
Year P/B Ratio Change
Not enough data for the provided dates.
P/B ratio for similar companies or competitors
Company P/B Ratio P/B Ratio Difference Country
6.3419 -
US
6.2413 -
NL
- -
CH
- -
KR
3.4612 -
BE